Failure of Treatment with First‐Line Lopinavir Boosted with Ritonavir Can Be Explained by Novel Resistance Pathways with Protease Mutation 76V
The Journal of Infectious Diseases2009Vol. 200(5), pp. 698–709
Citations Over TimeTop 10% of 2009 papers
Monique Nijhuis, Annemarie M. J. Wensing, Wouter F.W. Bierman, Dorien de Jong, Ron M. Kagan, Axel Fun, C. A. J. J. Jaspers, Karin A. M. Schurink, Michael A. van Agtmael, Charles A. Boucher
Abstract
The HIV protease substitution L76V, in combination with M46I, confers clinically relevant levels of lopinavir resistance and represents a novel resistance pathway to first-line lopinavir/r therapy.
Related Papers
- → Impact of 48 week lopinavir/ritonavir monotherapy on blood cell-associated HIV-1-DNA in the MONARK trial(2010)23 cited
- → Pharmacokinetics and Virological Efficacy after Switch to Once-Daily Lopinavir-Ritonavir in Treatment-Experienced HIV-1-Infected Children(2011)18 cited
- → Safety, Efficacy and Development of Resistance under the New Protease Inhibitor Lopinavir/Ritonavir: 48-Week Results(2004)20 cited
- → Impact of lopinavir-ritonavir exposure in HIV-1 infected children and adolescents in Madrid, Spain during 2000-2014(2017)8 cited
- → Response to: “Assessment of Baseline HIV Viral Load as a Risk Factor for Loss of Virologic Suppression in Protease Inhibitor-Based Monotherapy Trials”(2010)